Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR6 | P51684 | 1/20 | 0.62 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.62 |
| ▸ | REN | P00797 | 2/20 | 0.46 |
| ▸ | HTT | P42858 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | CA12 | O43570 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | CA9 | Q16790 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18760262 | 0.89 | CCR6 (0.53) | CCR6PAX8RENHTTSMN1; SMN2 | |
| SCHEMBL5557184 | 0.89 | CCR6 (0.58) | CCR6PAX8ALDH1A1LMNACA12 | |
| SCHEMBL10232646 | 0.87 | CCR6 (0.57) | CCR6PAX8ALDH1A1LMNACA12 | |
| SCHEMBL8777350 | 0.86 | CCR6 (0.54) | CCR6PAX8RENHTTALDH1A1 | |
| SCHEMBL23683127 | 0.85 | CCR6 (0.56) | CCR6PAX8HTTALDH1A1SMN1; SMN2 | |
| SCHEMBL10181395 | 0.83 | CCR6 (0.61) | CCR6PAX8ALDH1A1MAPK1L3MBTL1 | |
| SCHEMBL19795748 | 0.83 | CCR6 (0.58) | CCR6PAX8ALDH1A1LMNACA12 | |
| SCHEMBL759516 | 0.81 | CCR6 (0.66) | CCR6PAX8ALDH1A1MAPK1L3MBTL1 | |
| SCHEMBL9192713 | 0.81 | ALDH1A1 (0.52) | CCR6PAX8RENHTTALDH1A1 | |
| SCHEMBL7535687 | 0.80 | CCR6 (0.64) | CCR6PAX8ALDH1A1MAPK1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090023673-A1 | LIPID CONTAINING FORMULATIONS | BANK OF AMERICA, N.A. | 2009-01-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090023673-A1 | LIPID CONTAINING FORMULATIONS | LIPA, POLRMT, PHOSPHO1 | CCR6 2172/4885PAX8 3267/4885REN 4568/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.